An Open-Label, Pilot Study of Samarium - Sm 153 Lexidronam (Quadramet) in Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain.

Trial Profile

An Open-Label, Pilot Study of Samarium - Sm 153 Lexidronam (Quadramet) in Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Samarium-153-SM-lexidronam (Primary) ; Pamidronic acid; Zoledronic acid
  • Indications Bone metastases; Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Oct 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
    • 11 Jan 2016 Planned primary completion date changed from 1 Sep 2015 to 1 May 2016 as reported by ClinicalTrials.gov.
    • 31 Mar 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top